Shelter Pharma Peer Comparison

BSE: 543963

₹38.00

₹0.54 (1.44%)

As on 24-Sep-2026IST

Market cap

₹64 Cr

Revenue (TTM)

₹51 Cr

P/E Ratio

7.1

P/B Ratio

1.1

Div. Yield

0 %

Edit

	Shelter Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	64	37,045	28,110	16,796	15,453
Revenue (₹ Cr)	51	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	7.24	1,018.97	497.77	603.02	270.18
Net Margin (%)	14.28	10.47	20.72	22.63	23.29
RoE (%)	18.88	21.30	28.49	19.61	14.45
Price to Earnings	7.09	36.63	56.47	27.85	56.12
Price-To-Book	1.06	7.08	13.91	4.82	7.45

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Shelter Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	50.66	7,896.00	1,476.84	2,386.88	1,200.09
Total Income	50.68	7,968.78	1,497.35	2,421.45	1,244.53
Total Expenditure	40.60	6,427.14	1,153.58	1,704.30	693.24
EBITDA	10.06	1,468.85	323.26	682.58	506.84
Depreciation	0.27	384.13	65.55	60.61	54.37
EBIT	9.79	1,084.73	257.71	621.98	452.47
Interest	0.13	175.78	8.30	2.41	1.04
Other Income	0.02	72.79	20.51	34.57	44.45
Exceptional Items	--	-10.38	76.40	--	--
Profit before Tax	9.68	971.35	346.33	654.13	494.55
Provision for Tax	2.44	263.88	86.22	168.50	122.91
Profit after Tax	7.24	707.47	260.11	485.63	371.64

Liabilities (₹ Cr)

	Shelter Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	42.72	4,446.19	1,524.81	2,817.37	1,812.72
Minority Interest	--	195.37	--	--	--
Non-Current Liabilities	0.95	811.91	189.39	466.05	37.47
Current Liabilities	4.63	2,668.27	465.69	470.16	184.06
Total Liabilities	48.34	8,121.73	2,179.88	3,753.59	2,034.25

Assets (₹ Cr)

	Shelter Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	15.03	3,565.87	1,040.38	1,418.43	899.01
Current Assets	33.28	4,555.86	1,139.50	2,335.16	1,135.24
Total Assets	48.34	8,121.73	2,179.88	3,753.59	2,034.25
Total Debt*	1.04	731.70	136.01	0.00	0.38
Net Current Assets	28.65	1,887.59	673.81	1,865.00	951.18
Contingent Liabilities	--	393.94	8.97	4.82	3.91

Cashflow (₹ Cr)

	Shelter Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	5.48	851.71	317.40	391.52	244.52
Cash Flow from Investing Activities	-7.13	-94.00	-298.16	-615.65	-159.99
Cash from Financing Activities	0.03	-813.96	24.96	-6.23	-98.77
Net Cash Inflow / Outflow	-1.62	-56.25	44.21	-230.35	-14.24

Ratios

Profitability Ratios

	Shelter Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	25.07	22.49	23.45	25.50	29.62
ROE (%)	18.88	19.19	18.54	18.94	22.26
ROA (%)	16.14	8.94	12.97	13.34	19.90
EBIT Margin (%)	19.90	19.52	23.28	30.05	45.94
Net Margin (%)	14.28	8.88	17.37	20.06	29.86
Cash Profit Margin (%)	14.82	13.61	22.05	22.79	35.50

Growth Ratios

	Shelter Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	26.58	18.59	-5.24	4.54	18.01
EBIT Growth (%)	14.65	19.81	-27.65	4.50	18.31
Net Profit Growth (%)	16.73	34.10	-13.32	3.13	20.62
EPS Growth (%)	16.73	30.75	-13.32	3.12	20.62
Book Value Growth (%)	19.80	50.94	18.89	20.94	18.74

Valuation Ratios

	Shelter Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	5.78	29.84	59.57	27.24	47.19
Price / Book Value	1.00	4.58	10.17	4.71	9.67
Dividend Yield (%)	0.97	0.28	0.10	0.46	0.64
EV/EBITDA	3.92	13.55	44.72	18.35	31.81
Market Cap (₹ Cr)	41.85	20,327.45	15,494.53	13,228.83	17,537.35

Solvency Ratios

	Shelter Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.03	0.17	0.09	0.00	0.00
Short term debt to equity ratio	0.00	0.11	--	--	0.00
Current Ratio	7.19	1.71	2.45	4.97	6.17
Quick Ratio	4.40	0.98	1.62	3.53	4.87
Interest Coverage	72.95	6.53	42.74	271.97	475.76

Operating Efficiency Ratios

	Shelter Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	18.70	25.36	21.38	40.63	43.47
Asset Turnover	1.13	1.01	0.74	0.66	0.64
Receivable days	66.01	87.83	85.17	132.12	132.49
Inventory Days	82.22	78.64	90.97	102.08	68.07
Payable days	9.68	174.97	137.94	133.54	123.94
Cash Conversion Cycle	138.55	-8.50	38.21	100.66	76.63

Annual
Quarterly